Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438664 | 1.00 | CYP11B2 (0.54) | CYP11B2CYP11B1CYP19A1BCAT2MAOA | |
| SCHEMBL22713726 | 0.85 | CYP11B1 (0.53) | CYP11B2CYP11B1BCAT2MAOAMAOB | |
| SCHEMBL17541790 | 0.85 | CYP11B2 (0.52) | CYP11B2CYP11B1CYP19A1MAOAMAOB | |
| SCHEMBL29438633 | 0.84 | CYP11B2 (0.77) | CYP11B2CYP11B1 | |
| SCHEMBL25299690 | 0.84 | CYP11B2 (0.77) | CYP11B2CYP11B1 | |
| SCHEMBL16827426 | 0.83 | BCAT2 (0.46) | CYP11B2CYP11B1BCAT2MAOAMAOB | |
| SCHEMBL29438665 | 0.83 | BCAT2 (0.46) | CYP11B2CYP11B1BCAT2MAOAMAOB | |
| SCHEMBL22725954 | 0.83 | AOC3 (0.55) | CYP11B2CYP11B1BCAT2MAOAMAOB | |
| SCHEMBL14158182 | 0.81 | BCAT2 (0.53) | CYP11B2CYP11B1BCAT2MAOAMAOB | |
| SCHEMBL22725966 | 0.80 | AOC3 (0.56) | CYP11B2CYP11B1CYP19A1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-4215524-A1 | COMPOUND SERVING AS THYROID HORMONE BETA RECEPTOR AGONIST AND USES OF COMPOUND | Sunshine Lake Pharma Co., Ltd. (CN) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022057845-A1 | COMPOUND SERVING AS THYROID HORMONE β RECEPTOR AGONIST AND USES OF COMPOUND | 广东东阳光药业有限公司 | 2022-03-24 | — | — | WO | disclosed |
| CN-114195764-A | Compound as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | CYP11B2 201/4885CYP11B1 178/4885CYP19A1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.